Sponsored by
This is the final report on the phase 2 trial of ICT-107 for newly diagnosed GBM. It was declared a "failure" because the median survival did not improve enough. However, digging into the details, there are many patients who responded very well, and there were no side effects. As with the other immunotherapy trials, this had a long survival tail which does not get reflected in the mean survival statistics. I still feel this is a worthy treatment to try.
I just heard (and reported in a recent news blast) that this vaccine is making a comeback - it was sold to a new company who hopefully will run another trial in the subgroups that benefitted!